EDITOR,-A recent paper demonstrates very clearly the dangers of allowing those who may benefit financially from the results of a study to be involved in reporting that study. The double blind trial of recombinant human erythropoietin (r-HuEpo) in preterm infants reported by Emmerson, et al was supported by Cilag Ltd.' The r-HuEpo used was supplied by Cilag Ltd and one of the authors is employed by Cilag Ltd.
The abstract of the paper outlines the form of the double blind study. It reports a significant rise in the reticulocyte count in the r-HuEpo group, and a reduction in the number of transfusions needed compared with the placebo group, and some differences in haematological indices. The abstract concludes: 'The study provides strong evidence for the efficacy of r-Hu-Epo in stimulating erythropoiesis and reducing the requirement for transfusions for anaemia of prematurity'.
I suspect I was not alone in at first accepting that abstract at face value. It was only on reading the whole paper that I discovered that the abstract is dangerously misleading. In fact there was no significant difference in the proportions of each group requiring transfusion, there was no significant difference in the mean volume of blood transfused in each group, and at no time during the study or three months' follow up was there any significant difference in mean haemoglobin concentration between the two groups.
By far the most misleading aspect of the abstract, however, was the failure to mention that 20% of the r-Hu-Epo group died within a month of the end of the trial, while no infant in the placebo group died. Three out of 15 infants receiving r-HuEpo while in hospital died within four weeks of being discharged home, one from volvulus and gut infarction, and two from sudden infant death syndrome (SIDS The deaths of the infants in the clinical trial of r-HuEpo in preterm infants are a concern shared by many, not least by the authors of the paper, however that this should lead to very obvious warnings in the abstract is strongly refuted.
It is inappropriate to group the three deaths together. One of the deaths was an infant who developed an acute volvulus of the gut after cessation of treatment, and this was a clear cause of death. Of more concern are the two infants who died from SIDS, four weeks after stopping treatment, both having received different r-HuEpo doses. Statistically the chance of two infants dying of SIDS within one group of 15 infants is small, but this does not confirm a causal relationship.
No attempt was made to mislead the reader. Throughout the paper there is open discussion of these deaths, including in the subjects and methods section where the premature termination of the study was reported. This demonstrates that the authors took these deaths extremely seriously, feeling it inappropriate to continue the double blind trial without breaking the code and analysing the data. In addition to very careful scrutiny of the data for the whole group and for the two SIDS infants, an extensive search of the world experience (published and unpublished) was made for other cases. No other cases of SIDS have occurred with the use of r-HuEpo. The doses employed in some other studies have been several times higher, and taking this and the numbers treated in all studies the significance of the possible association of SIDS and r-HuEpo is reduced.'-3 These points are made clearly in the paper. Theoretical mechanisms whereby r-HuEpo may have resulted in SIDS are given in the discussion, and the whole approach of the paper cannot be considered to be dismissive of the danger.
The authors did not feel that a warning of the dangers of using r-HuEpo in preterm infants was appropriate, for the reasons stated above, and in that respect it was not recorded in the abstract which, being a brief summary, should in no way replace reading the full paper.
The authors take strong exception to the suggestion that Cilag's commercial interests influenced the publication. 
